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Summary Alteration in MHC class I expression may be used by cancer cells to avoid immune destruction.
Much experimental evidence supports this idea, although survival studies are very scarce. To investigate
whether the presence or absence of HLA-A, -B and -C antigens in laryngeal carcinoma influences survival, a
series of 60 primary laryngeal tumours treated surgically and normal tissues were evaluated in frozen sections
for the expression of MHC class I antigens and tumour-infiltrating leucocytes (CD3, CD4, CD8, CD1Ib, CD1,
CD20 and CDI6), using monoclonal antibodies and the APAAP technique. Long-term follow-up from the
patients is available, ranging from 6 to 10 years. Thirteen tumours presented total HLA-ABC loss, five selective
losses of HLA-A antigens and one absence of HLA-B antigens. Total losses were statistically associated with
several clinical and pathological parameters, but there were no differences regarding tumour-infiltrating
leucocytes. After conducting a prospective study, only T and N staging and scoring according to Glanz's
malignancy classification were found to be independently related to patients' outcome. From our data, we
conclude that neither complete loss of HLA class I antigens nor tumour-infiltrating leucocytes appear to
influence survival in squamous cell carcinoma of the larynx.
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MHC class I antigens are membrane glycoproteins involved
in effective killing by cytotoxic T cells, which require HLA
class I compatibility between T cells and target cells
(Thorsby, 1982; Festenstein and Garrido, 1986). Alterations
in HLA-ABC expression may be one method used by cancer
cells to avoid immune destruction (Garrido, 1987). Decreased
HLA expression has been discovered in several human
tumours, including breast, lung, skin, colorectal, gastric and
laryngeal carcinomas (L6pez-Nevot et al., 1986, 1989;
Redondo et al., 1991; Ruiz-Cabello et al., 1989). However,
few studies have analysed the mechanisms responsible for
such alterations. In previous papers, we investigated changes
in the expression of HLA class I antigens during malignant
transformation of the laryngeal epithelium and some
mechanisms involved (Esteban et al., 1989), and we found
several clinical and pathological correlations between HLA-
ABC losses and aggressiveness (Esteban et al., 1990a). MHC
class II antigens were only found in verrucous cell
carcinomas, thus DR expression seems to be associated with
tumours with excellent prognosis (Esteban et al., 1990b). On
the other hand, laryngeal tumours are often characterised by
an inflammatory reaction that follows the growth of
neoplastic elements, but its prognostic value and its
functional significance remain to be determined. The aim of
the present work is to present the long-term results of the
series and to evaluate the prognostic significance of MHC
class I antigens and tumour-infiltrating leucocytes (TILs) in
patients with laryngeal carcinoma after long-term follow-up.
Materials and methods
Patients
Sixty patients with squamous cell carcinoma of the larynx
were included in the study. None of them received radio-
therapy or chemotherapy before surgery. All were male. Age
ranged from 44 to 75 years (average 58.68 years). Tumours
were classified as originating from the supraglottic region
(33,55%), glottis (18,30%), subglottis (2,3.3%) and pyriform
sinus (3,5%). Four cases were considered transglottic (6.7%).
Thus, there were 57 laryngeal and three hypopharyngeal
tumours in the study. Surgical techniques consisted of
cordectomy (four cases), frontolateral laryngectomy with
epiglottoplasty as popularised by Harvey Tucker (two
cases), supraglottic horizontal laryngectomy (12 cases) and
total laryngectomy (42 cases). Neck dissection was performed
at clinical stage IV disease and at stage III as indicated by the
presence of or high risk of cervical metastasis and by the
specific site of the primary tumour. A total of 22 patients
underwent ipsilateral and 18 bilateral functional neck
dissections. Radical ipsilateral neck dissection was done in
three patients, and a bilateral staged procedure in four. Post-
operative radiation therapy was decided on an individual
basis by a multispeciality joint tumour board (otolaryngol-
ogist, oncologist and pathologist), and radiotherapy was
chosen for 29 patients. Basically, radiotherapy was chosen for
all T4 and/or node-positive tumours, since functional neck
dissection allows pathological staging for the neck. There
were four TI, four T2, 37 T3 and 15 T4 carcinomas. Forty-
two patients were classified as NO, six NI, eight N2 and four
N3. Follow-up ranged from 66 to 112 months, available for
all patients. At present, 19 patients have died: 12 patients as a
result of the disease (five neck relapses, two pharyngeal
recurrences, three cases with pulmonary metastasis, one case
with neck relapse and lung metastasis, one stomal recurrence)
and there were seven deaths unrelated to the laryngeal disease
(one myocardial infarction; 1 car crash; 1 chronic pulmonary
obstructive disease; one patient committed suicide, and three
died as a result of other tumours: lung, prostate and
oesophagus).
Location and diameter of the primary tumour, T and N
pathological staging (according to UICC, 1992 version),
number of lymph nodes from the neck dissection and number
of lymph node metastases, pathological global staging, blood
group and Rh of the patient, age, smoking and alcohol
consumption, first symptom-diagnosis intervals and follow-
up (in months) were recorded for each case.
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Pathological analysis
Tumours were classified into three grades by the UICC
modified Broders' system (Wahi, 1972), and all were scored
according to Glanz's (Glanz, 1984) and Jakobsson's
(Jakobsson et al., 1973) grading systems for squamous
cancer. In addition, two modifications to the former were
included [Crissman et al. (1984) and the authors' modifica-
tion]. The histological grading of malignancy was based upon
the tumour cell population (structure, differentiation, nuclear
polymorphism and mitosis) and tumour-host relationship
(mode of invasion, stage of invasion, vascular invasion and
cellular response). Histological analyses were performed
without any knowledge of the clinical stage, treatment or
further course of the disease.
Monoclonal antibodies, alkaline immunophosphatase technique
The immunohistochemical technique and monoclonal anti-
bodies against MHC class I antigens were described in
previous publications (Esteban et al., 1989, 1990). The
following MAbs were included against leucocyte determi-
nants: GRT2, which recognises the common leucocyte
antigen CD45 (Huelin et al., 1988); Leu 4, Leu 3a and Leu
2a, against CD3, CD4 and CD8 respectively (Becton
Dickinson); Bear-I against CD1 lb (Keizer et al., 1985);
OKT6 (Ortho) against CDI; GRM1 against CD16 (Ruiz-
Cabello et al., 1988); and IOM-1 against CD20 (immuno-
tech).
Interpretation of immunohistological results
A tumour was classified as negative when no staining was
detected in any of ten randomly chosen microscopic fields,
and as positive when all tumour cells were stained in ten
fields. In our series, no specimens showed a heterogeneous
pattern of staining for the HLA-ABC antigens (Esteban et
al., 1990b). Tumour-infiltrating leucocytes were averaged
after counting the number of stained cells in ten microscopic
high-power fields.
Statistical analysis
We used the proportional hazards model as specified by Cox
(1972). In this model, a positive regression coefficient means
an increased risk of death for a given level with respect to the
baseline level, whereas a negative coefficient indicates the
opposite effect. Selection of the most predictive variables was
based on a stepwise algorithm with a nominal significance
level of 10%. ANOVA was used to compare groups of
tumour-infiltrating leucocytes.
Results
Expression of HLA-A, B, C antigens
Normal laryngeal mucosa was always positive for HLA-ABC
antigens. Losses of these antigens were always related to
malignancy. We found 13 total losses of HLA-ABC antigens,
five selective losses of HLA-A and one of HLA-B antigens.
Study of tumour-infiltrating leucocytes
Analysis of the tumour-infiltrating leucocytes was performed
in most cases (50 patients). The infiltrating cells were
composed of T cells and some macrophages (Table I).
Langerhans cells, natural killer (NK) cells and B cells were
sparse. No significant differences were found between MHC
class I antigen expression and immunophenotype of TILs.
Survival analysis
The survival analysis calculated from 60 patients showed a
high probability of tumour-related death for the T, N and
score according to Glanz's classifications (Table II). No
discriminating effect on tumour-related death, however, could
be detected on the expressional status of HLA-A, B or C/fJ2m
antigens. In addition, the cell composition in the infiltrates
did not affect the frequency of metastasis and the 5 year
survival.
Discussion
In addition to genetic alterations, some events are probably
needed to acquire the malignant phenotype of a tumour.
Thus, cellular malignant transformation is frequently
associated with alteration in MHC antigens (Garrido et al.,
1993), and these alterations may profoundly affect the way in
which the tumour behaves, decreasing or enhancing specific
anti-tumoral immune mechanisms (Festenstein, 1987). It has
been shown in several animal models that the immunogeni-
city of tumours depends on the expressional status of MHC
class I antigens of tumour cells (Hammerling et al., 1987). In
a recent study, selective growth arrest and phenotypic
reversion of prostate cancer cells by phenylacetate, a non-
toxic differentiation inducer, was accompanied by an
increased amount of HLA transcripts (Samid et al., 1993).
Therefore, regulation of tumour HLA expression might be a
strategy for the evasion of immune surveillance by the
malignant cells.
Concerning the molecular basis ofthe defect in HLA class I
expression in our tumours, we previously reported (Esteban et
al., 1989) by Southern and Northern blot analysis that
transcriptional regulation of HLA expression is likely to be
involved in this phenomenon. Further evidence supporting this
concept includes stimulation studies with y-interferon (IFN) in
tumours with undetectable expression of HLA-A, -B or -C
antigens (Ruiz-Cabello et al., 1989), and modulation of MHC
class I expression by oncogene activation (Versteeg et al.,
Table II Coefficients, standard errors and odds ratio for the Cox
regression model
Variable Coefficient Standard error Odds ratio
N 0.7464 0.2881 2.1094
T 1.2032 0.6551 3.3307
Glanz's score 0.7113 0.2789 2.0366
Table I Leucocytic infiltratea in tumours with total and selective HLA-ABC losses comparison of
HLA-ABC positive tumours vs total or selective losses
Tumours (number of cases studiedfor each subpopulation)
CD HLA-ABC (+) Selective loss P-Value HLA-ABC (-) P-Value
CD3 42.369 (35) 41.420 (5) 0.9368 34.460 (10) 0.3798
CD4 27.305 (37) 22.240 (5) 0.4599 18.336 (10) 0.0733
CD8 19.335 (37) 23.900 (5) 0.5329 21.373 (11) 0.699
CDllb 15.956 (35) 14.58 (5) 0.6908 20.54 (10) 0.0807
CD20 2.968 (31) 2.68 (5) 0.8470 2.75 (6) 0.8746
CD16 4.145 (30) 2.42 (5) 0.4116 5.21 (7) 0.5572
CDI 8.883 (36) 7.26 (5) 0.7145 4.814 (7) 0.0982
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1988). Clinical studies on the MHC expressional status of
malignant tumours and survival are very scarce (Moller et al.,
1991; Passlick et al., 1994). In our study, we showed that total
loss of HLA-A, -B and -C antigens in laryngeal carcinomas is
not a prognostic factor. However, series including a greater
number of patients may improve the level of statistical
significance, as univariate analysis has shown a strong
relationship between HLA class I total loss and tumour
aggressiveness (Esteban et al., 1990b).
On the other hand, we have not found any significant
difference between class I expression and the immunopheno-
type of infiltrating cells, and also between these TILs and
survival. The exact role that lymphocytes may play against
laryngeal cancer is unknown. There are few papers
investigating the role of TILs in head and neck cancer, and
results are inconclusive (Hiratsuka et al., 1984; Rabin et al.,
1984; Harabuchi et al., 1985; Wolf et al., 1986; Boheim et al.,
1987; Zeromski et al., 1986; Guo et al., 1987). In breast and
colon tumours, two reports performed multivariate analysis
and they found that the amount of lymphocytic infiltrate was
independently predictive of the risk of death (Marques et al.,
1990; Kubota et al., 1992), although they did not measure the
immunophenotype of this infiltrate. Others have shown T
cells to be a favourable prognostic sign, whereas B cells are
generally not predominant in various human cancers
(Shimokawara et al., 1982). In contrast, some reports show
evidence that tumours are stimulated into growth by host
cells in the tumour stroma (Stewart and Tsai, 1993). In this
context, in vitro studies demonstrated that tumour-infiltrating
leucocytes display an immune inhibitory effect (Fulton, 1987;
Vose and Bonnard, 1982). Other authors report important
functional deficiencies in T cells (Gorski et al., 1994; Fu et
al., 1989).
Concerning Langerhans cells, a high density of these cells
has been considered of favourable prognosis for patients with
squamous cell carcinoma of the larynx in the univariate
analysis (Gallo et al., 1991). However, we found a very small
proportion of Langerhans cells in our cases with no influence
on prognosis.
The prospective study presented here confirms the
paramount prognostic implication of T, N and Glanz's
score on the relative risk of tumour-related death in our
group of patients. It is important to stress these aspects in
view of the reliability of our statements on MHC antigen
expression and prognosis.
Although our survival results are very conclusive, we
are reluctant to accept the idea that there is a null
response of immune mechanisms. We cannot rule out
different HLA class I expression in residual tumour cells
after putatively curative resection, since a small proportion
of cells with different expression are frequently present in
human tumours (Cordon-Cardo et al., 1991). On the other
hand, the increased susceptibility of HLA class I-negative
tumours to lysis by NK cells may influence metastatic
potential and survival (Karre et al., 1986), and finally,
selective losses of HLA class I allelic products on tumours
with positive expression for HLA-A, -B and -C antigens
may frequently be present and also influence the metastatic
potential (Honma et al., 1994). Our group is currently
investigating HLA phenotype in invasive breast carcinomas
using anti-HLA polymorphic antibodies, and more than
88.5% of the tumours showed an altered HLA tumour
phenotype, when compared with the peripheral blood
lymphocytes of each patient (Cabrera et al., 1996). In
that paper, HLA-ABC total losses were found in a similar
proportion to those in laryngeal carcinomas; however, it
seems that those laryngeal tumours presenting 'normal'
expression of HLA class I antigens could have allelic
losses not shown with the MAbs used in our 1990 study,
as demonstrated in breast cancer. Thus, alterations in
HLA class I expression could be so common that
statistical analysis may not detect the importance of
HLA expression in tumour cells.
In conclusion, total loss of HLA-A, -B and -C expression
is not associated with a high risk of tumour-related death.
Further investigations with HLA allelic typing and other
immunological markers are needed to evaluate prognosis in
laryngeal carcinomas.
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